Dynavax to Participate in Webcast Hosted by Pacific Growth Equities, LLC
BERKELEY, Calif., Jan. 24 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced that Pacific Growth Equities, LLC will host an informal conversation with Dr. Dino Dina, President and CEO, and Dr. Dan Levitt, Chief Medical Officer, of Dynavax to further discuss the Phase 2/3 TOLAMBA™ data announced on January 18, 2006.
Interested parties may listen to the webcast live at http://www.dynavax.com by clicking on the "Events" tab under the heading, "Investors." The webcast is also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at http://www.fulldisclosure.com or by visiting any of the investor sites in CCBN's Individual Investor Network. Institutional investors can access the call via CCBN's password-protected event management site, StreetEvents, at http://www.streetevents.com . A telephonic replay will be available two hours after the call ends at the following numbers: Encore Dial In: 800-642-1687 OR 706-645-9291. Encore Dates: 1/25/2006 at 2:00PM PST (5:00PM EST) - 2/1/2006 at 11:59PM (EST).
About Dynavax
Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Dynavax's pipeline includes: TOLAMBA™, a ragweed allergy immunotherapeutic, that has completed a large-scale Phase 2/3 clinical trial and is in a supportive clinical trial in ragweed-allergic children; HEPLISAV™, a hepatitis B vaccine that is currently in a pivotal Phase 3 clinical trial; a cancer therapy currently in a Phase 2 clinical trial; and an asthma immunotherapeutic that has shown preliminary safety and pharmacology in a Phase 2a clinical trial.
SOURCE: Dynavax Technologies Corporation
CONTACT: Jane M. Green, PhD, Vice President, Corporate Communications of
Dynavax Technologies Corporation, +1-510-665-4630, or jgreen@dvax.com